PharmaCyte Biotech (PMCB) Receives Nasdaq Non-Compliance Notice for Minimum $1.00 Bid Price
PharmaCyte Biotech (PMCB) received a Nasdaq non-compliance notice for failing to meet the minimum $1.00 bid price requirement.
Stoke Therapeutics (STOK) CEO Sells 10,000 Shares Under Pre-Arranged Plan
Stoke Therapeutics CEO Edward M. Kaye sold 10,000 shares for $150,000 total, according to an SEC Form 4 filing.
Merck & Co., Inc. (MRK) Files 424B5: Offering $8 Billion in Notes
Merck & Co., Inc. (MRK) filed a 424B5 prospectus supplement for an $8 billion debt offering, with proceeds potentially funding the acquisition of Cidara Therapeutics.
Coming soon
This is Pharma8k's, a brand new site by boogy boogy that's just getting started. Things will be up and running here